{
    "id": "dbpedia_4255_2",
    "rank": 49,
    "data": {
        "url": "https://www.immunize.org/vaccines/vaccine-timeline/",
        "read_more_link": "",
        "language": "en",
        "title": "Vaccine History Timeline",
        "top_image": "https://www.immunize.org/wp-content/uploads/cropped-favicon-32x32.png",
        "meta_img": "https://www.immunize.org/wp-content/uploads/cropped-favicon-32x32.png",
        "images": [
            "https://www.immunize.org/wp-content/uploads/Immunize.svg",
            "https://www.immunize.org/wp-content/uploads/vaccines/history-timeline-vintage-1024x512.png 1024w, https://www.immunize.org/wp-content/uploads/vaccines/history-timeline-vintage-300x150.png 300w, https://www.immunize.org/wp-content/uploads/vaccines/history-timeline-vintage-768x384.png 768w, https://www.immunize.org/wp-content/uploads/vaccines/history-timeline-vintage-1536x768.png 1536w, https://www.immunize.org/wp-content/uploads/vaccines/history-timeline-vintage.png 1920w",
            "https://www.immunize.org/wp-content/uploads/icons/immunize.org-logo-white.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2023-06-22T20:39:58+00:00",
        "summary": "",
        "meta_description": "Not long ago we celebrated the 225th anniversary of Edward Jenner’s first smallpox vaccination in 1796. The development of vaccines continued at a fairly slow rate until the last several decades when new scientific discoveries and technologies led to rapid advances in virology, molecular biology, and vaccinology. Here we present a timeline of the vaccine- […]",
        "meta_lang": "en",
        "meta_favicon": "https://www.immunize.org/wp-content/uploads/cropped-favicon-32x32.png",
        "meta_site_name": "Immunize.org",
        "canonical_link": "https://www.immunize.org/vaccines/vaccine-timeline/",
        "text": "2024\n\nCDC approves ACIP recommendations for RSV for adults, DTaP-IPV-Hib-HepB (Vaxelis®️), COVID-19, Influenza, and Pneumococcal Vaccines. June 28, 2024\n\nCDC Recommends Updated 2024-2025 COVID-19 and Flu Vaccines for Fall/Winter Virus Season. June 27, 2024\n\nCDC Updates RSV Vaccination Recommendation for Adults. June 26, 2024\n\nCDC HAN Health Advisory “Increased Risk of Dengue Virus Infections in the United States.” June 25, 2024\n\nFDA approves PCV21 (Capvaxive, Merck) in individuals 18 years of age and older. June 17, 2024\n\nFDA updates advice to manufacturers of COVID-19 Vaccines (2024-2025 Formula): If feasible Use KP.2 Strain of JN.1-Lineage. June 13, 2024\n\nFDA approves expanded age indication for Arexvy (GSK) the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk. June 10, 2024\n\nFDA approves Mrsevia (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older. May 31, 2024\n\nCDC HAN Health Advisory “Meningococcal Disease Cases Linked to Travel to the Kingdom of Saudi Arabia (KSA): Ensure Pilgrims are Current on Meningococcal Vaccination.” May 20, 2024\n\nACIP recommends use of an additional updated 2023–2024 COVID-19 vaccine dose for adults aged 65 Years and older. April 25, 2024\n\nACIP recommendations for use of pentavalent meningococcal vaccine (Pfizer) for persons 10 years and older. April 18, 2024\n\nCDC HAN Health Advisory “Highly Pathogenic Avian Influenza A(H5N1) Virus: Identification of Human Infection and Recommendations for Investigations and Response.” April 5, 2024\n\nCDC HAN Health Advisory “Increase in Invasive Serogroup Y Meningococcal Disease in the United States.” March 28, 2024\n\nCDC HAN Health Advisory “Increase in Global and Domestic Measles Cases and Outbreaks: Ensure Children in the United States and Those Traveling Internationally 6 Months and Older are Current on MMR Vaccination.” March 18, 2024\n\nCDC posts guidance for constrained U.S. Td supply, 2024. March 6, 2024\n\nCDC updates and simplifies respiratory virus recommendations. March 1, 2024\n\nCDC endorses ACIP recommendations for additional dose 2023-24 COVID-19 vaccine for adults ages 65 years and older and Chikungunya vaccine for travelers and lab workers. February 28, 2024\n\nCDC urges mpox vaccination for those eligible given continued U.S. mpox cases. February 12, 2024\n\nCDC COCA Now – Stay alert for measles cases. January 25, 2024\n\nCDC’s guidance on using Td for infants and children who should not receive acellular pertussis-containing vaccines. January 23, 2024\n\nCDC COCA Now – Information on respiratory syncytial virus (RSV) vaccine administration errors in young children and pregnant people. January 22, 2024\n\nMMWR – ACIP Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — US, 2024. January 11, 2024\n\nMMWR – ACIP Recommended Immunization Schedule for Adults Aged 19 Years or Older — US, 2024. January 11, 2024\n\nCDC COCA Now – Updated guidance for healthcare providers on increased supply of nirsevimab to protect young children from severe respiratory syncytial virus (RSV) during the 2023–2024 season. January 5, 2024\n\n2023\n\nACIP recommends Inactivated Polio Vaccine (IPV) for all adults 18 years and older known or suspected to be unvaccinated or incompletely vaccinated against polio. December 8, 2023\n\n2024 U.S. Recommended Immunization Schedule for Adults Aged 19 years or older posted. November 16, 2023\n\n2024 U.S. Recommended Immunization Schedule for Children and Adolescents Aged 18 years or younger posted. November 16, 2023\n\nACIP recommends use of Tick-Borne Encephalitis (TBE) vaccine for certain travelers and any laboratory workers who work with the virus. November 10, 2023\n\nFDA approves the first chikungunya vaccine (IXCHIQ, Valneva), approved for individuals 18 years of age and older who are at increased risk of exposure to chikungunya virus. November 9, 2023\n\nCDC approves ACIP recommendations for meningococcal and mpox vaccines, approves the 2024 US Recommended Child and Adolescent Immunization Schedule and Recommended Adult Immunization Schedule, including addenda for new and updated vaccine recommendations. October 26, 2023\n\nCDC HAN- Limited Availability of Nirsevimab in the United States—Interim CDC Recommendations to Protect Infants from Respiratory Syncytial Virus (RSV) during the 2023–2024 Respiratory Virus Season. October 23, 2023\n\nFDA approves Penbraya (PFR) for ages 10 through 25 years, a pentavalent vaccine protects against five meningococcal bacteria groups – A, B, C, W and Y – which are known to commonly cause the disease. October 20, 2023\n\nACIP recommends use of updated COVID-19 vaccines for persons 6 months of age and older. October 10, 2023\n\nACIP recommends RSV vaccine (Abrysvo, Pfizer) for pregnant persons at 32–36 weeks’ gestation using seasonal administration (September–January in most of the United States) to prevent RSV-associated lower respiratory infections in infants less than 6 months of age. October 6, 2023\n\nFDA amends EUA to include Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula), now authorized for use in individuals 12 years of age and older. Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent) is no longer authorized for use in the United States. October 3, 2023\n\nACIP recommendations on the use of PCV20 (Pfizer) for children. September 29, 2023\n\nCDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth. September 22, 2023\n\nCDC recommends everyone 6 months and older get an updated COVID-19 vaccine. Updated COVID-19 vaccines from Pfizer-BioNTech and Moderna will be available later this week. September 12, 2023\n\nFDA approves and authorizes emergency use of updated mRNA vaccines (Moderna, Pfizer) for 2023-24. The updated mRNA vaccines are each approved for individuals 12 years of age and older and are authorized under emergency use for individuals 6 months through 11 years of age. Bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. September 11, 2023\n\nACIP recommendations for using pneumococcal vaccine in adults 19 and older. September 8, 2023\n\nACIP recommendations for using nirsevimab (Beyfortus, Sanofi) in infants under 8 months old born during or entering their first RSV season and for infants and children 8–19 months old who are at increased risk of severe RSV disease entering their second RSV season. August 25, 2023\n\nACIP recommendations for the prevention and control of seasonal influenza with vaccines for the 2023–24 influenza season. August 25, 2023\n\nFDA approves the first vaccine (Abrysvo, Pfizer) for pregnant individuals at 32–36 weeks gestational age, to prevent RSV in infants up to 6 months old. August 21, 2023\n\nCDC adopts ACIP recommendation for using nirsevimab (Beyfortus, Sanofi), a long-acting monoclonal antibody product shown to reduce the risk of both hospitalizations and healthcare visits for RSV in infants by about 80 percent. August 3, 2023\n\nFDA approved Ebola vaccine (Ervebo, Merck) to include individuals 12 months and older. July 27, 2023\n\nACIP recommendations for using RSV (respiratory syncytial virus) vaccine (Pfizer Abrysvo and GSK Arexvy) in older adults. July 21, 2023\n\nFDA approved Cyfendus (Emergent BioSolutions) (Anthrax Vaccine Adsorbed, Adjuvanted) a two-dose anthrax vaccine for post-exposure prophylaxis use for adults aged 18–65. July 20, 2023\n\nCDC adopted 2023–24 ACIP flu vaccination recommendations, to be published in the summer. June 29, 2023\n\nCDC adopted ACIP recommendations for using RSV vaccine in adults 60 and older using shared clinical decision-making. June 29, 2023\n\nACIP interim recommendations for using bivalent mRNA COVID-19 vaccine in children aged 6 months to 5 years, adults 65 and older, and those with immunocompromising conditions. June 16, 2023\n\nFDA approved Abrysvo (Pfizer) RSV (respiratory syncytial virus) vaccine, approved for individuals 60 and older. May 31, 2023\n\nEnd of COVID-19 Public Health Emergency. May 11, 2023\n\nFDA approved the first RSV (respiratory syncytial virus) vaccine. Arexvy (GSK) was approved for individuals 60 and older. May 3, 2023\n\nFDA authorized additional doses of Pfizer-BioNTech COVID-19 vaccine, bivalent for ages 6 months through 4 years with immunocompromise who had previously received three 0.2 mL doses (Pfizer-BioNTech COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine, bivalent). April 28, 2023\n\nFDA approves Prevnar 20 (Pfizer) for infants and children, now approved for 6 weeks and older. April 27, 2023\n\nCDC simplified COVID-19 vaccine recommendations to allow older and immunocompromised adults to get a second dose of the bivalent vaccine. April 19, 2023\n\nFDA amended EUAs of Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines. Bivalent vaccines were to be used for all doses given to individuals 6 months and older. Monovalent COVID-19 vaccines were no longer authorized for use in the United States. April 18, 2023\n\nFDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as a booster dose for certain children 6 months through 4 years old. March 14, 2023\n\nCDC released the 2023 recommended immunization schedule for children, adolescents, and adults. February 10, 2023\n\n2022\n\nCDC expanded updated COVID-19 vaccines to include children 6 months through 5 years old. December 9, 2022\n\nFDA authorized updated (bivalent) COVID-19 vaccines for children as young as 6 months old. December 8, 2022\n\nACIP recommended Priorix (GSK) as an additional option to prevent MMR according to existing vaccine recommendations and off-label uses. November 18, 2022\n\nACIP interim recommendations for using bivalent booster doses of COVID-19 vaccines. November 11, 2022\n\nCDC allowed 18-year-olds and older the option to receive a Novavax monovalent booster instead of an updated (bivalent) Pfizer-BioNTech or Moderna booster if they have completed primary series vaccination but have not previously received a COVID-19 booster. October 19, 2022\n\nFDA issued an EUA for the Novavax COVID-19 vaccine to provide a first booster dose to individuals 18 and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine was not accessible or clinically appropriate and to individuals 18 and older who elect to receive the Novavax COVID-19 vaccine. October 19, 2022\n\nCDC recommended expanding the use of updated (bivalent) COVID-19 vaccines (Pfizer-BioNTech for children 5–11 years old, Moderna for children and adolescents 6–11 years old) to children 5–11 years old. October 12, 2022\n\nFDA amended EUAs to authorize bivalent formulations of COVID-19 vaccines (Pfizer-BioNTech for children 5–11 years old, Moderna for children and adolescents 6–17 years old) for use as a single booster dose two months after a primary series or booster dose. October 12, 2022\n\nFDA approved previously licensed Boostrix (GSK) as the first vaccine specifically for use during the third trimester of pregnancy to prevent pertussis (whooping cough) in infants younger than 2 months old. October 7, 2022\n\nACIP recommendation for using the cholera (Vaxchora, Emergent Biosolutions) vaccine. September 30, 2022\n\nACIP recommended the use of PCV15 as an option for pneumococcal vaccination for children under 19 years old, using current PCV13 dosing and schedules. September 16, 2022\n\nThe United States joined a list of 30 countries that meet WHO criteria for circulating vaccine-derived poliovirus (cVDPV). September 13, 2022\n\nCDC recommended the first updated bivalent COVID-19 booster. September 1, 2022\n\nFDA amended EUAs of Moderna and Pfizer-BioNTech COVID-19 vaccines to authorize bivalent formulations for use as a single booster dose at least two months following primary or booster vaccination. August 31, 2022\n\nCDC released ACIP recommendations for using influenza vaccines for the 2022-23 influenza season. August 26, 2022\n\nCDC recommended Novavax COVID-19 vaccine for adolescents 12–17 years old as a primary series option. August 22, 2022\n\nFDA expanded age indication of Novavax COVID-19 vaccine, adjuvanted EUA to include individuals 12 years and older. August 19, 2022\n\nFDA issued EUA of JYNNEOS (Bavarian Nordic A/S) allows subcutaneous administration to those under 18 and intradermal administration of vaccine to 18-year-olds and older to increase vaccine supply. August 9, 2022\n\nFDA issued EUA for Novavax, COVID-19 vaccine adjuvanted to provide a two-dose primary series to individuals 18 and older. August 9, 2022\n\nACIP interim recommendation for using Novavax COVID-19 vaccine in adults 18 and older. July 13, 2022\n\nFDA expanded age indication of Comirnaty (Pfizer-BioNTech) vaccine to include adolescents 12–15 years old for a two-dose primary series (the EUA remained in effect for additional doses for immunocompromised for 12 years and older and for booster doses). July 8, 2022\n\nACIP published interim recommendations for using Moderna and Pfizer-BioNTech COVID-19 vaccines in children 6 months to 5 years old. June 28, 2022\n\nCDC endorsed ACIPʼs recommendation of Modernaʼs COVID-19 vaccine for those 6-17 years old, in addition to its already recommended use in children 6 months through 5 years old and adults 18 and older. June 24, 2022\n\nCDC endorsed the ACIP recommendation that all children 6 months through 5 years old should receive a Moderna or Pfizer-BioNTech COVID-19 vaccine. All children, including children who have already had COVID-19, should get vaccinated. June 18, 2022\n\nFDA amended Moderna COVID-19 EUA to include the use of the vaccine in individuals 6 months through 17 years old. June 17, 2022\n\nFDA amended Pfizer-BioNTech COVID-19 EUA to include the use of the vaccine in individuals 6 months through 4 years old. June 17, 2022\n\nFDA approved expanded age recommendation for Vaxneuvance (PCV15, Merck) pneumococcal vaccine to individuals 6 weeks and older. June 17, 2022\n\nFDA approved the Priorix (GSK) (Measles, Mumps, and Rubella vaccine, Live) vaccine for the prevention of measles, mumps, and rubella in individuals 12 months and older. June 3, 2022\n\nACIP published recommendations for using Jynneos (smallpox and monkeypox, now known as Mpox) vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses. May 27, 2022\n\nCDC recommended that children 5–11 years old should receive a booster shot five months after their initial Pfizer-BioNTech vaccination series, strengthens its recommendation that those 12 and older who are immunocompromised and those 50 and older should receive a second booster dose at least four months after their first. May 19, 2022\n\nFDA amended the EUA and expanded eligibility for Pfizer-BioNTech COVID-19 vaccine booster dose to children 5–11 years old. May 17, 2022\n\nACIP updated rabies recommendations: use of modified preexposure prophylaxis vaccination schedule to prevent human rabies. May 6, 2022\n\nACIP recommended universal hepatitis B vaccination in adults 19–59 years old. April 1, 2022\n\nFDA authorized and CDC recommended a second COVID-19 vaccine booster for certain individuals. March 29, 2022\n\nFDA amended EUA and authorizes additional presentation of Moderna COVID-19 vaccine for booster vaccination doses (dark blue caps with purple border labels). March 29, 2022\n\nACIP recommended using the Moderna COVID-19 vaccine in adults 18 and older, with considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines. March 18, 2022\n\nACIP recommended two additional groups for the use of the Ebola vaccine. February 22, 2022\n\nCDC released the 2022 recommended immunization schedules for children and adolescents, as well as for adults, on its website. February 18, 2022\n\nFDA approved COVID-19 vaccine Spikevax (Moderna) for individuals 18 and older. (The EUA remained in effect for the third primary series dose and booster dose.) January 31, 2022\n\nCDC published ACIP updated recommendations for adults to use PCV15 and PCV20 pneumococcal vaccines. January 28, 2022\n\nCDC published ACIP recommendations for using recombinant zoster (shingles) vaccine in immunocompromised adults. January 21, 2022\n\nCDC published ACIP updated interim recommendations for using the Janssen (Johnson & Johnson) COVID-19 vaccine. January 21, 2022\n\nFDA shortened the interval to a booster dose of Moderna COVID-19 vaccine to five months. January 7, 2022\n\nCDC endorsed ACIPʼs recommendation to expand eligibility of booster doses to those 12–15 years old. CDC recommends that all adolescents 12–17 years old should receive a booster shot five months after their initial Pfizer-BioNTech vaccination series. January 5, 2022\n\nCDC recommended Pfizer-BioNTech booster five months after completing the primary series. CDC recommends moderately or severely immunocompromised children 5–11 years old receive an additional primary dose of the Pfizer-BioNTech COVID-19 vaccine 28 days after their second shot. January 4, 2022\n\nFDA amended EUA Pfizer-BioNTech vaccine (COVID-19); expanded use of a single booster dose to include 12–15-year-olds, shortened time to booster dose to at least five months, and allowed for third primary dose for certain immunocompromised children 5–11 years old. January 3, 2022\n\n2021\n\nCDC published ACIP recommendations for using the dengue vaccine. December 17, 2021\n\nFDA revised Janssen fact sheets to include contraindications and risks of TTS (thrombosis and thrombocytopenia syndrome). December 14, 2021\n\nFDA and CDC expanded Pfizer-BioNTech booster recommendations to 16–17-year-olds. December 9, 2021\n\nFDA approved PreHevbrio (VBI Vaccines) for adults 18 and older. November 30, 2021\n\nCDC recommended that all 18-year-olds and older get a COVID-19 booster. November 29, 2021\n\nFDA amended EUAs for COVID-19 mRNA vaccines for using booster doses for 18-year-olds and older. November 19, 2021\n\nCDC published ACIP interim recommendations for using Pfizer-BioNTech COVID-19 vaccine in children 5–11 years old. November 5, 2021\n\nFDA authorized EUA for Pfizer-BioNTech COVID-19 vaccine for children 5–11 years old. October 29, 2021\n\nCDC published ACIP recommendations for COVID-19 additional primary and booster doses. October 29, 2021\n\nFDA amended EUAs of all COVID-19 vaccines, allowing for booster doses, and mix-and-match doses in eligible individuals. October 20, 2021\n\nFDA approved expanded age indication for Flucelvax Quad (Seqirus), licensed for 6-month-olds and older. October 14, 2021\n\nFDA authorized booster dose of Pfizer-BioNTech COVID-19 vaccine for 65-year-olds and older, 18–64-year-olds at high risk of severe COVID-19, and 18–64-year-olds who have institutional or occupational exposure to SARS-CoV-2. September 22, 2021\n\nCDC released ACIP recommendations on using influenza vaccines for the 2021–22 influenza season. August 27, 2021\n\nFDA approved the first COVID-19 vaccine Comirnaty (Pfizer-BioNTech) for individuals 16 and older. (The EUA remains in effect for individuals 12 and older and for the third dose for immunocompromised individuals 12 and older). August 23, 2021\n\nFDA approved Ticovac (Pfizer), a vaccine to prevent tick-borne encephalitis (TBE) vaccine in individuals 1 year old and older. August 13, 2021\n\nFDA amended the emergency use authorizations (EUAs) for Pfizer-BioNTech and Moderna COVID-19 vaccines to allow the use of an additional dose in certain immunocompromised individuals. August 12, 2021\n\nFDA expanded the indication of the Shingrix vaccine to include adults 18 and older who are or will be at increased risk of zoster (shingles) due to immunodeficiency or immunosuppression caused by known disease or therapy. July 23, 2021\n\nFDA approved Vaxneuvance (Merck & Co.) pneumococcal 15-valent conjugate vaccine for adults 18 and older. July 16, 2021\n\nFDA revised fact sheets for Janssen COVID-19 vaccine (Johnson & Johnson), adding Guillain-Barré syndrome (GBS) warning and revising thrombocytopenia warning. July 8, 2021\n\nUpdate from ACIP: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients. July 6, 2021\n\nFDA revised EUA mRNA (Pfizer and Moderna) patient and provider fact sheets regarding the suggested increased risks of myocarditis and pericarditis following vaccination. June 25, 2021\n\nFDA approved Prevnar 20 (Pfizer) pneumococcal 20-valent conjugate vaccine for adults 18 and older. June 9, 2021\n\nACIP interim recommendations for the Pfizer-BioNTech COVID-19 vaccine in adolescents 12–15 years old. May 14, 2021\n\nFDA expanded the EUA of the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12–15 years old. May 10, 2021\n\nUpdated recommendation from ACIP for the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome (TTS) among vaccine recipients. April 27, 2021\n\nCDC and FDA lifted the recommended pause of use of the Johnson & Johnson (Janssen) COVID-19 vaccine in the United States after a review by ACIP. The use of the Janssen vaccine should resume. EUA fact sheets for Johnson & Johnson (Janssen) COVID-19 vaccine revised. April 23, 2021\n\nCDC and FDA recommended a pause in the use of the Janssen (Johnson & Johnson) COVID-19 vaccine in the United States out of an abundance of caution. A CDC Health Alert Network (HAN) was issued with recommendations. April 13, 2021\n\nCDC published ACIP interim recommendations for the Janssen (Johnson & Johnson) COVID-19 vaccine. March 2, 2021\n\nFDA issued emergency use authorization (EUA) for Janssen (Johnson & Johnson) COVID-19 vaccine. February 27, 2021\n\nCDC released the 2021 recommended immunization schedules for children and adolescents, as well as for adults, on its website. February 12, 2021\n\nCDC published ACIP recommendations for the Ebola vaccine. January 8, 2021"
    }
}